When to Increase or Decrease Your GLP-1 Dose (Doctor Explains)

The Dose Decision Most Patients Get Wrong

Dr. Spencer Nadolsky is an obesity medicine physician with a strong social media presence and a clinical practice focused entirely on weight management. This video on GLP-1 dose titration has over 104,000 views, and it addresses one of the most common sources of confusion and anxiety for patients: when should you go up on your dose, when should you stay put, and when should you actually go down?

The standard prescribing information for GLP-1 drugs provides a titration schedule that many patients and even some prescribers treat as a rigid script. Start at the lowest dose, increase every four weeks until you hit the target. But Dr. Nadolsky argues, correctly, that dose titration should be individualized based on how you are responding and tolerating the medication, not based on a one-size-fits-all calendar.

His core principle is straightforward: the right dose is the lowest dose that gives you meaningful results with tolerable side effects. Going higher is not always better. Some patients get excellent results at moderate doses and gain nothing but worse side effects from pushing to the maximum. Others genuinely need the highest dose to achieve their treatment goals. The goal of titration is to find your personal sweet spot, not to blindly follow the package insert.

When to Increase, Hold, or Decrease

Dr. Nadolsky lays out clear criteria for each decision. Increasing the dose makes sense when your current dose is well tolerated (minimal side effects), you have plateaued in your weight loss or blood sugar improvement for at least two to four weeks, and you have not yet reached your treatment goal. All three conditions should be met. Increasing because you have been on the same dose for a month, even though it is still working and you are still losing weight, is unnecessary and may introduce side effects that were not there before.

Holding at your current dose is appropriate when you are seeing ongoing results (even if they have slowed down), when side effects are present but manageable, or when you are at a dose that feels sustainable and you want to see how far it takes you before considering an increase. Dr. Nadolsky is a proponent of patience at each dose level, noting that some patients see continued improvement for eight to twelve weeks at a single dose before truly plateauing.

Decreasing the dose is the option many patients do not realize they have. If side effects are significantly affecting your quality of life, if you have reached your treatment goals and want to find a lower maintenance dose, or if you have lost weight to the point where your body may need less medication, stepping down is a legitimate clinical decision. Some patients who reached the maximum dose during active weight loss find they can maintain their results at a lower dose, reducing both side effects and cost.

What the Video Gets Right

The individualized approach is the biggest strength of this content. Dr. Nadolsky pushes back against the "escalate to maximum" mentality that can dominate GLP-1 prescribing. His criteria for dose changes are clear, clinically sound, and empowering for patients who may feel pressured to follow a rigid schedule. The idea that the right dose is the lowest effective dose is a principle that applies to most medications, and hearing it applied specifically to GLP-1 drugs is valuable.

He also addresses the psychological component of dose decisions. Some patients feel that staying at a lower dose means they are not trying hard enough or not getting the full benefit of the medication. Nadolsky reframes this: staying at a dose where you are comfortable and seeing results is smart medicine, not half-measures. This reframing can reduce the anxiety that some patients feel about their dose level.

What It Misses

The video does not address the insurance and pharmacy complications that often drive dose decisions. Some insurance plans require patients to demonstrate they have tried lower doses before approving higher ones, while others cover specific doses but not others. These practical constraints sometimes override clinical judgment in ways that frustrate both patients and prescribers.

There is also limited discussion of what happens during dose transitions. Going up in dose often brings a temporary return of side effects that had resolved. Going down in dose can sometimes lead to increased appetite before a new equilibrium is reached. Knowing what to expect during these transitions would help patients ride them out with less anxiety.

Questions to Bring to Your Doctor

This video gives you the framework to take ownership of your dose conversation:

Ask your doctor what specific metrics they are using to evaluate whether your current dose is working. Weight loss trajectory, blood sugar numbers, appetite changes, and side effect severity should all factor in.

Ask whether staying at your current dose longer is an option before increasing. If you are still seeing progress, there may be no clinical reason to escalate.

Ask about a dose reduction if you have reached a maintenance phase. Lower doses mean fewer side effects, lower cost, and potentially better long-term sustainability.

Ask about what a weight-loss plateau actually looks like versus a normal slowdown. A true plateau is typically defined as no change for at least four to six weeks despite consistent medication use and dietary adherence. Normal fluctuations week to week are not plateaus.

Who Should Watch This

Every patient on a GLP-1 drug should watch this, especially if you are approaching a dose increase and feeling uncertain. Dr. Nadolsky's framework turns dose decisions from a source of anxiety into a structured, collaborative process between you and your doctor. It is also useful for patients who have been pushed to maximum doses and are wondering whether stepping back might actually improve their experience. The message that the right dose is personal, not universal, is one that every GLP-1 patient needs to hear.

The concept of a maintenance dose that Nadolsky introduces toward the end of the video is one of the most underdiscussed aspects of GLP-1 treatment. Once you have reached your weight loss goal, the question becomes: what is the minimum dose needed to maintain your results? Some patients can step down significantly from their peak treatment dose and maintain most of their weight loss at a much lower and more tolerable dose. Others find that any dose reduction leads to weight regain and need to stay at or near their treatment dose long-term. Figuring out your personal maintenance dose is a process of careful experimentation guided by regular monitoring, and it deserves the same thoughtful approach that the initial titration received.

The psychological dimension of dose decisions that Nadolsky touches on is more significant than many patients realize. In online GLP-1 communities, there can be an implicit competition around dose levels, with some patients feeling inadequate if they are on a lower dose than others or feeling pressure to move up when they are doing well where they are. This social pressure can lead to unnecessary dose increases that produce worse side effects without meaningful additional benefit. Nadolsky's message that the right dose is personal and that lower is not worse if it is working is an important counterweight to these community dynamics.

For patients navigating the cost implications of dose decisions, it is worth knowing that in some cases, lower doses cost the same as higher doses because the medication is sold in tiered pen devices rather than priced per milligram. In other cases, particularly with compounded formulations, lower doses do cost less. Understanding the financial structure of your specific medication and formulation can help you evaluate whether a dose reduction would have financial benefits in addition to potentially improved tolerability. This is a practical consideration that rarely enters clinical conversations but matters to patients who are paying out of pocket or have high copays.

The broader takeaway from this video is about patient agency. Too many patients feel like passive recipients of their medication protocol, following instructions without understanding the reasoning or knowing that they have a voice in the process. Nadolsky empowers patients to see dose decisions as collaborative and criteria-based rather than automatic and prescriber-driven. This shift in mindset, from patient as passive recipient to patient as informed collaborator, tends to produce better outcomes, better adherence, and higher satisfaction with treatment across the entire GLP-1 journey.

The concept of "good enough" results deserves more airtime in the GLP-1 conversation. Not every patient needs to hit the clinical trial averages to consider their treatment successful. If you have lost enough weight to resolve your sleep apnea, normalize your blood sugar, and reduce your cardiovascular risk, but you have not reached the 15-20% weight loss seen in trials, that can absolutely be a successful treatment outcome that justifies maintaining your current dose rather than pushing higher. Treatment success should be defined by your personal health goals and risk reduction, not by comparison to population averages or other patients' results. Dr. Nadolsky's framework supports this individualized definition of success, and it is a message that more patients need to hear.